Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 4247 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

No further problems in Tysabri safety review

Three confirmed cases of multifocal leukoencephalopathy (PML), a rare demyelinating disease of the central nervous system, had previously been reported in patients treated with Tysabri (natalizumab), which Biogen